ImmuniT Platform for Improved Neoantigen Prediction in Lung Cancer
These findings highlight ImmuniT's potential to expand the repertoire of actionable tumor antigens and improve personalized immunotherapy strategies, particularly for patients with limited response to existing treatments.
Authors
- Stephanie J. Hachey (ORCID: https://orcid.org/0000-0002-0314-3459)
- Hari B. Keshava (ORCID: https://orcid.org/0000-0002-9506-2719)
- Christopher C.W. Hughes (ORCID: https://orcid.org/0000-0002-3223-830X)
- Alexander G. Forsythe (ORCID: https://orcid.org/0000-0002-5185-0705)
Institutions
- Simon Fraser University (CA)
- University of California, Irvine (US)
- Irvine University (US)
Publication Details
- Journal
- Vaccines
- Published
- 2025-08-29
- DOI
- https://doi.org/10.3390/vaccines13090921
- Citations
- 1
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- U.S. Department of Defense
- National Institutes of Health
- National Center for Advancing Translational Sciences